TCL6 and renal cell carcinoma: Similarly, TCL6 has also been shown to be involved in development of RCC as a tumor suppressor (Rysz et al. 2022) and interestingly, artificial increase of TCL6 in cancer cells sensitizes them to paclitaxel, which could pose a novel therapeutical opportunity (Chen et al. 2020).